Thursday 7 March 2024 6:00pm to 7:00pm
Keynes Lecture Theatre, King’s College King's College, King's Parade Cambridge, CB2 1ST
About
An enlightening talk and discussion on a career in Academia and Business led by Professor Tony Kouzarides. Following the talk, take advantage of the chance to network and socialize over drinks and food at The Lab Cocktail Bar
Tony did his bachelors’ degree at Leeds University and his PhD at the University of Cambridge. He then did postdoctoral work at the MRC Laboratory of Molecular Biology in Cambridge and at New York University Medical Centre. He returned to the UK to set up his own lab at the Gurdon Institute.
The Kouzarides lab has been studying epigenetic modifications for many years, starting with the identification of the first human enzymes to modify chromatin in 1996. His lab has identified and characterised many chromatin modification pathways and showed their involvement in cancer. The lab is now investigating the functions of mRNA modifications and their connections to cancer. In close collaboration with STORM Therapeutics, the Kouzarides lab is targeting RNA modification pathways with small molecule inhibitors, to develop drugs against cancer.
In the 22-year period of 1996-2017, Tony was listed in the top ten most-cited scientists at the University of Cambridge (in any field), as shown in the curated publication database of 100,000 top scientists world-wide (Ioannidis J et al, Plos Biology, 2019).
Tony is a co-founder and director of the Milner Therapeutics Institute, whose mission is to deliver better therapies through collaborations with industry. He is founder and director of Cambridge Gravity, an organisation for the promotion of science at the University of Cambridge. He is founder and patron of a cancer charity in Spain called Conquer Cancer (Vencer el Cancer). He is on the Scientific Advisory Board of the Institute of Cancer Research (UK) and on the Executive Board of the Cambridge Cancer Centre.
Tony is a co-founder and ex-director of Abcam plc, a publicly trading research reagents company in Cambridge, a co-founder and ex-director of Chroma Therapeutics, a drug discovery company based in Oxford, and a co-founder and current director of STORM Therapeutics, a drug discovery company based in Cambridge.